Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · brain-umap@2

SRR1370797

GTEX

bd0bc4b9-2d6d-52b7-b4ba-ffef08fbedbe

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
GTEX
cancer_type_detailed
—
subtype
—
cancer_type
GTEX
sex
Male

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INFLAMMATORY_RESPONSE+0.367
  • ANGIOGENESIS+0.339
  • KRAS_SIGNALING_DN+0.285
  • IL6_JAK_STAT3_SIGNALING+0.249
  • ALLOGRAFT_REJECTION+0.245
  • KRAS_SIGNALING_UP+0.242
  • COMPLEMENT+0.227
  • PANCREAS_BETA_CELLS+0.163
  • SPERMATOGENESIS+0.163
  • APICAL_SURFACE+0.146

Top 10 suppressed

  • MYC_TARGETS_V2-0.549
  • MYC_TARGETS_V1-0.541
  • OXIDATIVE_PHOSPHORYLATION-0.504
  • E2F_TARGETS-0.486
  • DNA_REPAIR-0.471
  • G2M_CHECKPOINT-0.433
  • UNFOLDED_PROTEIN_RESPONSE-0.406
  • ADIPOGENESIS-0.338
  • FATTY_ACID_METABOLISM-0.254
  • MITOTIC_SPINDLE-0.161

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR1467212
brain-umap@2
GTEX—0.888
2SRR1362464
brain-umap@2
GTEX—0.887
3640b257c-bbc3-4483-a7b5-191bb7ef5421
colon-landscapes@1
——0.886
4SRR659625
brain-umap@2
GTEX—0.885
5BS_NZ71XCG3
medullo-epn-umap@date-based
MedMedulloblastoma0.879
6SRR817758
brain-umap@2
GTEX—0.877
7SRR1414424
brain-umap@2
GTEX—0.876
8SRR1500639
brain-umap@2
GTEX—0.875
9SRR607478
brain-umap@2
GTEX—0.871
10SRR1498616
brain-umap@2
GTEX—0.871

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 23 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INFLAMMATORY_RESPONSE0.367Idelalisib— uncovered
ANGIOGENESIS0.339Remibrutinib— uncovered
KRAS_SIGNALING_DN0.285Remibrutinib— uncovered
IL6_JAK_STAT3_SIGNALING0.249Inavolisib— uncovered
ALLOGRAFT_REJECTION0.245Idelalisib— uncovered
KRAS_SIGNALING_UP0.242Inavolisib— uncovered
COMPLEMENT0.227Inavolisib— uncovered
PANCREAS_BETA_CELLS0.163Cobimetinib— uncovered
SPERMATOGENESIS0.163Inavolisib— uncovered
APICAL_SURFACE0.146Temsirolimus— uncovered
APICAL_JUNCTION0.143Inavolisib— uncovered
COAGULATION0.131Binimetinib— uncovered
ESTROGEN_RESPONSE_EARLY0.100Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.083Remibrutinib— uncovered
IL2_STAT5_SIGNALING0.076Idelalisib— uncovered
HYPOXIA0.070Idelalisib— uncovered
ESTROGEN_RESPONSE_LATE0.061Idelalisib— uncovered
ANDROGEN_RESPONSE0.060Inavolisib— uncovered
UV_RESPONSE_DN0.060Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.052Inavolisib— uncovered